Ratings Alvotech Nyse

Equities

ALVO

LU2458332611

Market Closed - Nyse Other stock markets 16:00:00 2024-05-02 EDT			5-day change	1st Jan Change
14.51 ^USD	+0.21%		+6.30%	+54.69%

04-30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
04-30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALVOTECH	+54.69%	4.06B	-
MODERNA, INC.	+26.28%	48.09B	B-
IQVIA HOLDINGS INC.	-3.99%	40.43B	B
LONZA GROUP AG	+46.96%	40.62B	A
CELLTRION, INC.	-6.20%	28.36B	C
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B	B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B	C+
BIO-TECHNE CORPORATION	-2.02%	11.88B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes